Octave Specialty Group (OSG) Conference presentation summary
Event summary combining transcript, slides, and related documents.
Conference presentation summary
17 Nov, 2026Platform and strategy
Built a 22-MGA specialty platform through 17 de novo launches and 5 established MGA acquisitions; business mix is 42% casualty, 34% A&H and 24% property.
Operates across the U.S., London and Bermuda; Octave Ventures backs new MGA launches, while Octave Partners focuses on acquisitions and bolt-ons.
MGA model earns commissions and fees on premiums placed, plus profit commissions, without taking balance-sheet insurance risk; 2026E premiums placed ~ $1.3B.
Third-party capacity exceeds $2.0B for current business and has historically been oversubscribed; capacity figure excludes Everspan.
Organic growth levers include de novo launches, product and geographic expansion, cross-selling, technology, capacity partnerships and broader distribution.
Insurance distribution
9M26 revenue was $195.3M, up 67% YoY; organic revenue growth was 35.5%.
9M26 adjusted EBITDA to shareholders was $43.4M, with a 22.2% margin; adjusted operating margin was 31.0%, up from 22.7% in 9M25.
2026E guidance: organic growth of 25%+ and adjusted EBITDA to shareholders of $45M+; segment guidance is based on updates made in August 2026.
De novo MGAs launched in 2024–25 drove ~60% of 9M26 organic growth; roughly half were EBITDA-positive at 3Q26. Established MGAs contributed ~40%.
Through 9M26, 7 U.S. product adjacencies launched; 3 additional product expansions were announced around the end of 3Q26.
Specialty P&C and Everspan
Everspan is a hybrid fronting carrier writing 30 programs at September 30, 2026; it cedes most risk to highly rated reinsurers and earns fronting fees and retained underwriting profit.
2026E gross written premium guidance is ~ $410M and adjusted EBITDA guidance is ~ $6M, up 58% vs. $3.8M in 2025; 3Q26 GAAP book value was $129M.
9M26 reported combined ratio was 115.1%; pro forma adjusted combined ratio was 96.7%, excluding litigation settlement, adverse development, severance and other items.
Everspan reported a 9M26 loss ratio of 70.7%, 260 bps better than 9M25; strategy includes shifting retained mix toward package and low-cat property and exiting underperforming programs.
Latest events from Octave Specialty Group
- 1H2026 revenue grew 59%, with $24M adjusted EBITDA and $2.0B+ third-party capacity.OSG
Conference presentation - Distribution growth and Everspan improvement lifted Q3 revenue and adjusted EBITDA amid P&C softening.OSG
Q3 2026 - Executing rapid global MGA growth with strong financials and a scalable, partnership-driven model.OSG
Investor presentation - Revenue up 51% and net loss narrowed, with strong Insurance Distribution and AI platform launch.OSG
Q2 2026 - Director elections, strategic transformation, and AI-driven growth initiatives were key highlights.OSG
AGM 2026 - Transformation completed, compensation aligned, and Board urges support for all proxy proposals.OSG
Proxy filing - Insurance Distribution revenue up 92%, total revenue up 66%, and adjusted EBITDA surged.OSG
Q1 2026 - Shareholders to vote on board, compensation, auditor, and new incentive plan after major transformation.OSG
Proxy filing - Revenue and premium up sharply, but net loss widened; Legacy/AAC sale pending approval.OSG
Q1 2025